Skip to NavigationSkip to content

Cancer Drugs Fund

Remembering the patient in the Cancer Drugs Fund debate

Today Simon is a bowel cancer patient who is able to enjoy his weekly round of golf.

After receiving the dreadful news in 2010 that his bowel cancer had returned and spread, his prospects of being alive for much longer than a few months looked bleak.

Simon was told his only hope was to be treated with the life-extending drug which would help shrink his tumours and enable him to receive surgery.

Government rips up blank cheque on cancer drugs

British prime minister David Cameron launched the CDF in 2010

Pharma has priced itself out of the Cancer Drugs Fund as the rising costs of its new oncology treatments sees Whitehall getting tougher with the industry.

In response, the British government has announced today that it will be extending the annual spend on the Cancer Drugs Fund (CDF) from £200 million a year to £280 million a year to accommodate the inexorable rise of cancer drug costs.

But where once the CDF would pay for any drug at any price, each medicine will now be scrutinised for its cost-effectiveness, and it will not pay out for medicines deemed too costly.

UK pharma teams up for better cancer drug access

Avastin packshot
Avastin remains the most commonly funded medicine via the Cancer Drugs Fund

UK at centre of Eisai plans

Halaven image
Eisai's growth will depend on its breast cancer drug Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as it tries to deal with global patent cliffs, according to the company’s European boss.

This year’s loss of protection for its Alzheimer’s drug Aricept (donepezil) has hit the firm hard but new launches point towards a brighter future, the manufacturer insists.

Avastin now available in UK for ovarian cancer

Avastin picture

Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK.

Avastin (bevacizumab) can now be used in combination with standard chemotherapy as a first-line treatment for women with advanced ovarian cancer after surgery.

Avastin is the first targeted drug to gain EU approval for the disease, as women with ovarian cancer were limited to treatment with chemotherapy and surgery until now.

Cancer drugs should not receive special funding - MS Society

Tyverb
Tyverb is one NICE-rejected treatment being funded by the Cancer Drugs Fund

 

Cancer Fund improving treatment access

Roche's Avastin
Roche’s Avastin has proved to be the most popular drug under the Fund

The Cancer Drugs Fund is dramatically improving access to new cancer medicines for patients in England – but its success is creating fears of postcode prescribing across the UK.

The Cancer Drugs Fund (CDF) was widely criticised after the first interim fund was established nearly a year ago, with complaints made about the difficulty of administering the fund. There were also early signs of an under spend in many CDF regional funds, but it now looks that these problems are being addressed.

NHS failed to use extra cancer drug funds

Roche’s Avastin (bevacizumab)
Roche’s Avastin (bevacizumab) - currently not recommended by NICE for use on the NHS - was the most requested drug under the interim Cancer Drugs Fund

The million pound fund set up to increase NHS uptake of new cancer drugs was widely underused, with just over half of the allocated money spent, according to a leading cancer charity.

The Cancer Drugs Fund was available between October 2010 to March 2011 and gave the health service an extra £50 million to help extend access to new cancer medicines, especially those

Doubts cast on new Cancer Drugs Fund

There are stark regional variations in the number of doctors using the government’s provisional Cancer Drugs Fund, according to a new report.

The findings come on the day the full version of the Cancer Drugs Fund is launched, promising an extra £200 million in drug funding each year for the next three years.

The survey, undertaken by Swiss pharma company Roche, looked at four regions across the south of England between October and March.

ABPI warns of postcode prescribing

ABPI

The ABPI has said the government’s forthcoming Cancer Drugs Fund could increase the problems of postcode prescribing.

The UK industry body issued its warning as it responded to the government’s consultation on the Cancer Drugs Fund, which is set to inject an extra £200 million per financial year into the NHS for oncology drugs that have not been recommended by NICE.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches